This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Rosuvastatin (Crestor) in Friedreich Ataxia

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Children's Hospital of Philadelphia
Friedreich's Ataxia Research Alliance
Information provided by (Responsible Party):
Children's Hospital of Philadelphia Identifier:
First received: March 5, 2016
Last updated: March 15, 2017
Last verified: March 2017
This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.

Condition Intervention Phase
Friedreich Ataxia Drug: Rosuvastatin Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia

Resource links provided by NLM:

Further study details as provided by Children's Hospital of Philadelphia:

Primary Outcome Measures:
  • Change in ApoA-1 serum protein levels from baseline to Week 12 visit [ Time Frame: 12 weeks ]
    Serum ApoA-1 protein levels will be collected at baseline and again at the Week 12 visit.

Secondary Outcome Measures:
  • Change in frataxin levels from baseline to Week 12 visit [ Time Frame: 12 weeks ]
    Frataxin levels in whole blood and buccal cells will be collected at baseline and again at the Week 12 visit.

  • Change in platelet metabolism from baseline to Week 12 visit [ Time Frame: 12 weeks ]
    Platelet metabolism will be assessed by performing liquid chromatography-mass spectrometry analysis on whole blood samples collected at baseline and again at the Week 12 visit.

Estimated Enrollment: 12
Study Start Date: May 2016
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosuvastatin (Crestor)
This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
Drug: Rosuvastatin
Daily oral administration of Rosuvastatin (10 mg) for 3 months
Other Name: Crestor

Detailed Description:
Friedreich ataxia (FRDA) is a progressive neurodegenerative disease of children and adults for which there is presently no therapy. Much of the current work in FRDA is aimed at finding new targets for drug therapies. Recent work at the University of Pennsylvania has discovered that serum ApoA-1 protein levels are lower in people with FRDA when compared with control levels. ApoA-1 is the main protein found in high-density lipoprotein (HDL) cholesterol and individuals with FRDA frequently have low HDL levels; the current study proposes to assess if administration of HMG-CoA reductase inhibitors for 3 months alters ApoA-1 protein levels in FRDA. Although the significance of ApoA-1 levels among FRDA patients is currently unknown, this study is proposed as an exploratory study to further examine this protein. If ApoA-1 protein levels increase over the course of treatment, future studies may additionally focus on examining this as a potential therapeutic treatment.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with Friedreich Ataxia confirmed by genetic testing
  • Adults between the ages of 18 and 65
  • Stable quinone dose (at least 1000 mg of Idebenone or 200 mg Coenzyme Q10) for 14 days prior to study entry and for the duration of the study
  • Females who are not pregnant or breast feeding, and who do not intend to become pregnant.
  • Subject has voluntarily signed consent form
  • Willingness and ability to comply with all study procedures

Exclusion Criteria:

  • Treatment with statins during the six previous months before study inclusion
  • Currently active or unresolved liver or kidney disease
  • Known history of renal insufficiency or creatine kinase >2 x ULN
  • Use of red rice yeast during the previous six months before inclusion
  • Current use of niacin and/or fibric acid derivatives
  • Current use of cyclosporine
  • Use of any investigational product within 30 days of baseline visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02705547

Contact: Cassandra Strawser 215-590-2314

United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19103
Contact: Cassandra Strawser    215-590-2314   
Principal Investigator: David Lynch, MD PhD         
Sponsors and Collaborators
Children's Hospital of Philadelphia
Friedreich's Ataxia Research Alliance
Principal Investigator: David Lynch, MD PhD Children's Hospital of Philadelphia
  More Information

Responsible Party: Children's Hospital of Philadelphia Identifier: NCT02705547     History of Changes
Other Study ID Numbers: 16-012659
Study First Received: March 5, 2016
Last Updated: March 15, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Children's Hospital of Philadelphia:
Friedreich Ataxia

Additional relevant MeSH terms:
Cerebellar Ataxia
Friedreich Ataxia
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on September 19, 2017